WG3: Translational medicine

Activities

This WG will pave the way towards a succesful transition from the preclinical to the clinical development of NRF2-targeted compounds. In this stage it is essential to identify reliable NRF2-related biomarkers to monitor disease progression and therapy outcome, equivalent both in patients and animal models. Thus, the main aim of WG3 will be to elaborate the template for future clinical trials on lead compounds identified in WG2 and to coordinate NRF2-related genetic and biochemical biomarker discovery in the selected NCDs.

Task

Members

A. Suha Yalcin

Aleksandra Piechota-Polańczyk

Aleksandra Zeljkovic

Ana Casas Guijarro

Andreas Daiber

Ángel Carracedo

Anton Terasmaa

Arif Kamil Salihoğlu

Arno Bourgonje

Artyom Pugachev

ASAF MARKO

Brigitte Winklhofer-Roob

Bruno Ramos-Molina

Camillo Rosano

Chakradhara Rao S Uppugunduri

Danijela Djukic-Cosic

Eugenia Carvalho

Eva Cano

George Spyrou

Gerasimos Sykiotis

Gina DeNicola

Harry van Goor

Helena Vieira

Ioannis Habeos

Ioannis P. Trougakos

Isabel Lastres-Becker

Isabel Varela-Nieto

IVANA STOJANOVIC

Joana Loureiro

Jordi Muntané

Josep Julve

Juan Antonio Moreno

Katarina Baralić

Katja Kanninen

Maria Carmo Pereira

Maria J Sanchez Quintero

Michel-Edwar Mickael

Miguel Seabra

Milen Georgiev

Natalija Jonić

Neda Djedovic

Niki Chondrogianni

Noemi Rotllan Vila

Roberta Foresti

Roberto Motterlini

Sara Zakaria

Sibel Kalyoncu Uzunlar

Sofia Azeredo Pereira

Susana Cadenas

Suzana Stanisavljevic

Tamara Gojkovic

Ugne Jonavice

Vera Marisa Costa

Vita Dolzan

Yahya Sohrabi